London Stock Exchange at Record Highs – Inside the Historic Market’s Brexit Battle and 2025 Revival

UK stocks today (6 Nov 2025): FTSE 100 edges lower before BoE decision; Sainsbury lifts profit guidance, ITV warns on Q4 ads, AstraZeneca beats

LONDON — Thursday, 6 November 2025

At a glance

  • FTSE 100 trades slightly lower as investors await the Bank of England’s rate call; sterling holds near multi‑month lows. [1]
  • Construction PMI slumps to 44.1 in October, the sharpest contraction in over five years, underscoring a soft UK backdrop. [2]
  • Earnings & updates:
    • J Sainsbury raises FY retail underlying operating profit guidance to “more than £1bn” and confirms an 11p special dividend. [3]
    • ITV flags ~9% YoY decline in Q4 total ad revenue and unveils £35m temporary savings. [4]
    • AstraZeneca beats Q3 revenue and core EPS but keeps full‑year guidance unchanged. [5]
    • Smith & Nephew shares drop ~9% on softer US knee‑implant sales. [6]
    • Diageo posts flat organic net sales in fiscal Q1 (volume +2.9%) and trims full‑year sales outlook. [7]
    • Hikma reaffirms 2025 guidance but lowers medium‑term growth targets. [8]
    • LSEG announces a private‑markets data partnership with Nasdaq. [9]

Market snapshot: waiting on Threadneedle Street

UK equities were fractionally lower by late morning, with traders staying cautious ahead of the Bank of England’s midday decision and press conference. The FTSE 100 drifted as much as about 0.3%, while sterling hovered near recent lows against major peers amid growth concerns and budget uncertainty later this month. [10]

Fresh data reinforced the slowdown narrative: the S&P Global/CIPS Construction PMI fell to 44.1 in October (from 46.2), marking the fastest drop in activity since May 2020 and the longest downturn since the financial crisis. Civil engineering led the decline, with housing also weak. [11]

One pocket of strength: UK bank shares modestly outperformed after reports the sector may avoid a punitive tax raid in the upcoming Budget, lifting the FTSE 350 Banks index. [12]


Big movers & newsmakers

Sainsbury: guidance upgrade, special payout

J Sainsbury (SBRY) said first‑half trading was ahead of expectations and raised its full‑year retail underlying operating profit target to “more than £1bn.” It also confirmed an 11p special dividend on 19 December and outlined additional buyback plans linked to its bank disposals. The retailer cited grocery volume growth, improving value perception and cost savings. [13]

ITV: strong Studios & digital, but Q4 ad headwinds

ITV (ITV) reported +2% group revenue YTD to £2.80bn, driven by +11% Studios and +15% digital ad growth. However, management warned Q4 total advertising revenue is expected to be down ~9% YoY, citing broad caution ahead of the late‑November Budget. ITV will make £35m temporary savings (including £20m by moving content into 2026) to offset the revenue hit. [14]

AstraZeneca: beats, but no guidance raise

AstraZeneca (AZN) delivered a Q3 beat on revenue and core EPS thanks to oncology and cardiovascular drugs, but left its full‑year outlook unchanged, which some investors had hoped would be lifted. The company highlighted pipeline progress and reiterated long‑term ambitions. [15]

Smith & Nephew: revenue miss bites

Smith & Nephew (SN.) shares fell around 9% after Q3 revenue (~$1.50bn) missed estimates, with US knee‑implant sales singled out as a weak spot. The company kept its annual revenue and margin guidance unchanged, but the US orthopaedics softness dominated sentiment. [16]

Diageo: flat volumes up, price/mix down; outlook nudged

Diageo (DGE) posted flat organic net sales in fiscal Q1 (volume +2.9%) as growth in Europe, LAC and Africa was offset by Chinese white spirits weakness and a softer US spirits market. Diageo now expects FY26 organic net sales to be flat to slightly down, but still targets ~$3bn free cash flow this year as its “Accelerate” cost‑saving programme progresses. [17]

Hikma: 2025 intact, medium‑term trimmed

Hikma (HIK) reaffirmed 2025 guidance (group revenue growth 4–6%; core operating profit $730–$750m), but revised lower its 2024–2027 CAGR and Injectables margin expectations as its Bedford US facility timeline pushes out toward late 2027. [18]

LSEG x Nasdaq: private‑markets data tie‑up

London Stock Exchange Group (LSEG) unveiled a strategic partnership with Nasdaq to distribute private‑markets datasets (including eVestment content) via LSEG Workspace and datafeeds—an extension of LSEG’s recent push into private‑company infrastructure. [19]


Why it matters

  • The BoE decision arrives into a weak domestic backdrop (construction slump, cautious consumers and advertisers), alongside a soft currency—all levers that can magnify policy impact on bank, housebuilder and domestically focused mid‑cap shares. [20]
  • Corporate updates show a bifurcated market: staples/retailers are leaning on cash returns and execution (Sainsbury), media is feeling the cyclical ad slowdown (ITV), while healthcare names are moving on pipeline and mix (AstraZeneca; Smith & Nephew). [21]
  • Banks’ relative outperformance today underlines how fiscal signals can swing sector leadership in the run‑up to November’s Budget. [22]

What to watch next (today)

  • Bank of England policy decision & vote split — market reaction in gilts, sterling, banks, and UK domestic cyclicals. [23]
  • Company calls and press briefings from today’s reporters (notably AstraZeneca, ITV, Diageo, Hikma) for colour on 2026 planning, cost actions, and demand signals. [24]

Sources & further reading

  • Market & macro: UK stocks and FX pre‑BoE; UK banks rally; UK Construction PMI. [25]
  • Company updates: Sainsbury H1 results; ITV Q3 trading update; AstraZeneca Q3; Smith & Nephew Q3 price reaction; Diageo F26 Q1; Hikma trading update; LSEG–Nasdaq partnership. [26]

This report is for information only and does not constitute investment advice. Market levels and share prices referenced above reflect conditions reported during the UK morning session on 6 November 2025.

Bloomberg Business News Live

References

1. www.reuters.com, 2. www.reuters.com, 3. corporate.sainsburys.co.uk, 4. www.itvplc.com, 5. www.reuters.com, 6. www.reuters.com, 7. www.diageo.com, 8. www.hikma.com, 9. www.tradingview.com, 10. www.reuters.com, 11. www.reuters.com, 12. www.reuters.com, 13. corporate.sainsburys.co.uk, 14. www.itvplc.com, 15. www.reuters.com, 16. www.reuters.com, 17. www.diageo.com, 18. www.hikma.com, 19. www.tradingview.com, 20. www.reuters.com, 21. corporate.sainsburys.co.uk, 22. www.reuters.com, 23. www.reuters.com, 24. www.reuters.com, 25. www.reuters.com, 26. corporate.sainsburys.co.uk

Stock Market Today

  • Stagwell Reports Q3 2025 Results: Revenue Growth, Palantir Partnership, and 2025 Guidance
    November 6, 2025, 8:55 AM EST. Stagwell Inc. (STGW) posted Q3 2025 results with Q3 Revenue of $743 million, up 4% YoY, and Net Revenue of $615 million, up 6%. Excluding Advocacy, Q3 Revenue rose 12% to $686 million. Q3 Net Income attributable to common shareholders was $25 million; EPS $0.09; Adjusted EPS $0.24. Adjusted EBITDA was $115 million (3% YoY), with YTD Adjusted EBITDA of $288 million. Net New Business added $122 million in Q3 (LTM $472 million). The company also announced a Palantir partnership. For 2025, management guides Total Net Revenue growth ~8%, Adjusted EBITDA $410-$460 million, and Free Cash Flow Conversion >45%.
  • Oscar Health (OSCR) Q3 2025 Earnings Preview: What To Look For
    November 6, 2025, 8:52 AM EST. OSCR investors are eyeing Oscar Health's Q3 2025 results due Nov 6. Street consensus calls for revenue of $3.08B and EPS of -$0.61, with the full-year outlook at $12.04B revenue and - $1.41 per share. Over the last 90 days, revenue estimates rose to $12.04B (2025) and $11.34B (2026) while earnings expectations declined to - $1.41 (2025) and - $0.47 (2026). In the prior quarter, actual revenue was $2.86B vs $2.89B expected, and earnings were - $0.89 vs - $0.46 expected. The stock traded higher ~3.8% after the last report. Analysts' price targets average $13.18 (range $8-$19.95), implying a potential downside to the current price of about 23%, though GuruFocus GF Value hints at an upside of 1.46% to $17.41. The consensus rating is Hold (3.3/5).
  • RPM International Named a Top 25 SAFE Dividend Stock (RPM)
    November 6, 2025, 8:50 AM EST. RPM International Inc. (RPM) earned a spot on Dividend Channel's S.A.F.E. 25, signaling an above-average DividendRank, a 2.0% yield, and a two-decade track record of dividend growth. The stock also plays a notable role in index funds, with RPM as a holding in the iShares S&P 1500 ETF (ITOT) and representing about 0.79% of the SPDR S&P Dividend ETF (SDY). The company pays an annualized $2.16 dividend, with the latest ex-date on 10/20/2025, underscoring a long history of reliable distributions across the Specialty Chemicals sector. Overall, RPM's combination of steady payments, long-tenured growth, and macro-sector exposure reinforce its place among growing dividend stocks.
  • Otter Tail OTTR Named Top 10 Dividend-Paying Utility Stock by Dividend Channel
    November 6, 2025, 8:48 AM EST. Otter Tail Corp. (OTTR) has been named a Top 10 dividend-paying utility stock by Dividend Channel, per its weekly DividendRank report. The analysis highlights OTTR's attractive valuation and strong profitability metrics within the utility sector, along with a long-term dividend history. DividendRank emphasizes seeking value with solid payout tracks, noting OTTR fits that profile. The stock offers an annualized dividend of $1.87, paid quarterly, with the most recent ex-date on 08/15/2024. The emphasis on consistent payouts and multi-year growth in key fundamentals helps explain its Top 10 ranking.
  • Oscar Health Sees 2026 Return to Profitability After Q3 Loss
    November 6, 2025, 8:46 AM EST. Oscar Health on Thursday posted a third-quarter (Q3) loss of $137.5 million (53 cents a share) but reiterated a path to profitability by 2026 as costs rise and markets shift. The insurer said membership rose more than 28% year over year to about 2.1 million, helping revenue climb to near $2.9 billion in the quarter. Management cited a higher-cost, sicker pool and said rate filings have been resubmitted to cover 2026 for roughly 99% of current members. Oscar still eyes a return to positive net income next year as it balances membership growth with profitability. With competitors like CVS Health's Aetna retreating from Obamacare in parts of the market, the market remains a target for Oscar's growth.
Westpac’s $7 Billion Windfall Ignites ASX Rally Despite Mining Slump – Nov 3, 2025
Previous Story

ASX Today: S&P/ASX 200 edges up 0.3% to 8,828 as gold miners shine; James Hardie halted, NAB slips — 6 Nov 2025

Wall Street Braces for Shutdown: Stocks Rally as Fed Cuts Loom – Tech & Defense in Focus
Next Story

Hong Kong stocks today (Nov 6, 2025): Hang Seng jumps 2.1% as chips & commodities surge; Pony.ai and WeRide sink on Hong Kong debut

Go toTop